tiprankstipranks
Advertisement
Advertisement

RNTX Stock Latest News

RNTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Pre-EarningsRNTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
22d ago
RNTX
Rein Therapeutics past the regulatory uncertainty, says H.C. Wainwright
PremiumThe Fly
Rein Therapeutics past the regulatory uncertainty, says H.C. Wainwright
24d ago
RNTX
Rein Therapeutics: Regulatory Overhang Removed and Phase 2 IPF Progress Underscore Best‑in‑Class Potential and Undervalued Upside
PremiumRatings
Rein Therapeutics: Regulatory Overhang Removed and Phase 2 IPF Progress Underscore Best‑in‑Class Potential and Undervalued Upside
24d ago
RNTX
Rein Therapeutics doses first patient in Phase 2 trial of LTI-03
PremiumThe Fly
Rein Therapeutics doses first patient in Phase 2 trial of LTI-03
2M ago
RNTX
Rein Therapeutics Completes Private Placement of Notes
PremiumCompany Announcements
Rein Therapeutics Completes Private Placement of Notes
2M ago
8K
RNTX
Rein Therapeutics Announces Immediate Board Director Resignation
PremiumCompany AnnouncementsRein Therapeutics Announces Immediate Board Director Resignation
2M ago
8K
RNTX
Rein Therapeutics downgraded to Hold from Buy at Brookline
Premium
The Fly
Rein Therapeutics downgraded to Hold from Buy at Brookline
3M ago
RNTX
Rein Therapeutics receives orphan drug designation from EMA for LTI-03
Premium
The Fly
Rein Therapeutics receives orphan drug designation from EMA for LTI-03
3M ago
RNTX
Rein Therapeutics Raises Capital via Private Note Offering
PremiumCompany Announcements
Rein Therapeutics Raises Capital via Private Note Offering
3M ago
8K
RNTX
Rein Therapeutics Ends Key Financial Agreements
PremiumCompany Announcements
Rein Therapeutics Ends Key Financial Agreements
5M ago
8K
RNTX
Rein Therapeutics: Buy Rating Driven by Innovative IPF Treatment and Strong Growth Potential
PremiumRatings
Rein Therapeutics: Buy Rating Driven by Innovative IPF Treatment and Strong Growth Potential
5M ago
RNTX
Rein Therapeutics Reports Q3 2025 Financial Results
PremiumCompany Announcements
Rein Therapeutics Reports Q3 2025 Financial Results
5M ago
RNTX
Rein Therapeutics’s LTI-03 Gains Momentum with FDA Clearance and Promising Trial Developments
PremiumRatingsRein Therapeutics’s LTI-03 Gains Momentum with FDA Clearance and Promising Trial Developments
6M ago
RNTX
Rein Therapeutics announces publication on LTI-03
Premium
The Fly
Rein Therapeutics announces publication on LTI-03
6M ago
RNTX
Rein Therapeutics upgraded to Buy from Hold at Brookline
Premium
The Fly
Rein Therapeutics upgraded to Buy from Hold at Brookline
6M ago
RNTX
Rein Therapeutics Resumes Phase 2 Trial for LTI-03
PremiumCompany Announcements
Rein Therapeutics Resumes Phase 2 Trial for LTI-03
6M ago
8K
RNTX
Rein Therapeutics receives FDA clearance to resume Phase 2 trial of LTI-03
PremiumThe Fly
Rein Therapeutics receives FDA clearance to resume Phase 2 trial of LTI-03
6M ago
RNTX
Rein Therapeutics Secures Third Pre-Paid Advance
PremiumCompany Announcements
Rein Therapeutics Secures Third Pre-Paid Advance
6M ago
8K
RNTX
Rein receives European regulatory approval to initiate Phase 2 trial of LTI-03
PremiumThe Fly
Rein receives European regulatory approval to initiate Phase 2 trial of LTI-03
7M ago
RNTX
Rein Therapeutics initiated with a Buy at H.C. Wainwright
PremiumThe FlyRein Therapeutics initiated with a Buy at H.C. Wainwright
7M ago
RNTX
Rein Therapeutics announces publication of data on LTI-03 in IPF
Premium
The Fly
Rein Therapeutics announces publication of data on LTI-03 in IPF
7M ago
RNTX
Rein Therapeutics Secures Second Advance in Funding Deal
Premium
Company Announcements
Rein Therapeutics Secures Second Advance in Funding Deal
8M ago
8K
RNTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >